FDA GMP Initiative Shifts Warning Letter Review Back To Centers
This article was originally published in The Tan Sheet
Executive Summary
The Center for Drug Evaluation & Research will begin reviewing GMP warning letters March 1 as part of FDA's initiative to create a risk-based approach to pharmaceutical manufacturing